This immunotoxin was achieved by conjugating/fusing the Anti-CD33 monoclonal antibody to gelonin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to leukemia cells. Once bind, the toxin enters cells by receptor-mediated endocytosis, then gelonin inhibits protein synthesis by damaging the 60S subunit of mammalian ribosomes. It was designed for treatment of leukemia.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-321-sdAb | Recombinant Anti-human CD33 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
There are currently no Customer reviews or questions for AGTO-L050G. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.